Obesity is a complex disease in which excessive body fat increases due to nutrient imbalance. Obesity is a medical problem requiring interventional treatment to manage and minimize the risk of other health problems, such as diabetes, high blood pressure, and heart disease etc. Up to now, most weight loss drugs solely restrict nutrient intake.
DA-1726 is a long acting oxyntomodulin peptide analog that can bind and activate both glucagon-like peptide-1 (GLP-1) and glucagon receptors. Activation of GLP-1 and glucagon receptors suppresses appetite and reduces nutrient intake. In addition, activation of glucagon receptors in adipose tissue elicits fat burning. Thus, DA-1726, designed as a well-balanced dual agonist, induces weight loss while effectively improving body composition. Moreover, hypoglycemic effects induced by GLP-1 receptor activation were maintained. Therefore, in pre-clinical animal models, DA-1726 induced superior weight loss and similar hypoglycemic effects when compared to a high dose semaglutide (an active ingredient of Wegovy®). DA-1726 also has therapeutic potential for MASH via ameliorating metabolic dysregulations.
[Note 1. source: Diabetes.co.uk. the global diabetes community, Anim Sci J. 2016;87(9):1090-1098 ]